Considering the large variety in TCR repertoire and antigen specificities, the canonical method of selecting the correct TCRs for engineering is through sequencing TCR α chain and β chain mRNAs from in vitro-cultured T cells of cancer patients, or using algorithmic predictions based of the CDR3 binding region of TCRs.42,46–48 The highly specific and directed nature of TCR–pMHC interaction prevent engineered TCR-T cell from targeting cells that do not express the specific tumor antigen and MHC restriction. This evidence concerns the gene HLA-C and neoplasm.